Alexander Drilon

38.6k total citations · 11 hit papers
382 papers, 13.1k citations indexed

About

Alexander Drilon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Alexander Drilon has authored 382 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 298 papers in Pulmonary and Respiratory Medicine, 221 papers in Oncology and 118 papers in Cancer Research. Recurrent topics in Alexander Drilon's work include Lung Cancer Treatments and Mutations (276 papers), Cancer Genomics and Diagnostics (107 papers) and Colorectal Cancer Treatments and Studies (79 papers). Alexander Drilon is often cited by papers focused on Lung Cancer Treatments and Mutations (276 papers), Cancer Genomics and Diagnostics (107 papers) and Colorectal Cancer Treatments and Studies (79 papers). Alexander Drilon collaborates with scholars based in United States, France and Germany. Alexander Drilon's co-authors include Marc Ladanyi, Emiliano Cocco, Maurizio Scaltriti, Maria E. Arcila, Mark G. Kris, Natasha Rekhtman, Charles M. Rudin, David M. Hyman, Ryma Benayed and Sai‐Hong Ignatius Ou and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Alexander Drilon

363 papers receiving 12.9k citations

Hit Papers

NTRK fusion-positive canc... 2015 2026 2018 2022 2018 2015 2019 2019 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. NTRK fusion-positive cancers and TRK inhibitor therapy
    2018 962 citations Emiliano Cocco, Maurizio Scaltriti et al. profile →
  2. Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
    2015 423 citations Paul K. Paik, Alexander Drilon et al. Cancer Discovery profile →
  3. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
    2019 409 citations Alexander Drilon et al. profile →
  4. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
    2019 366 citations James P. Solomon, Kerry Mullaney et al. profile →
  5. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions
    2017 331 citations Jaclyn F. Hechtman, Ryma Benayed et al. The American Journal of Surgical Pathology profile →
  6. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    2016 327 citations Alexander Drilon, Natasha Rekhtman et al. profile →
  7. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets
    2016 325 citations Natasha Rekhtman, M. Catherine Pietanza et al. Clinical Cancer Research profile →
  8. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
    2019 289 citations Ryma Benayed, Michael Offin et al. Clinical Cancer Research profile →
  9. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
    2016 268 citations Alexander Drilon et al. Journal of Thoracic Oncology profile →
  10. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
    2022 244 citations Vivek Subbiah, Jürgen Wolf et al. profile →
  11. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
    2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Alexander Drilon 8.0k 7.2k 4.5k 3.5k 1.8k 382 13.1k
James G. Christensen 7.7k 1.0× 9.0k 1.2× 9.8k 2.2× 3.7k 1.1× 2.4k 1.3× 189 18.5k
Maria E. Arcila 10.6k 1.3× 8.7k 1.2× 5.8k 1.3× 4.7k 1.3× 1.8k 1.0× 253 15.7k
Sai‐Hong Ignatius Ou 14.1k 1.8× 11.8k 1.6× 5.6k 1.2× 3.5k 1.0× 1.7k 0.9× 349 17.6k
Amita Patnaik 4.5k 0.6× 8.4k 1.2× 6.2k 1.4× 2.1k 0.6× 1.2k 0.7× 365 14.4k
Frederic J. Kaye 6.2k 0.8× 8.6k 1.2× 6.6k 1.5× 2.8k 0.8× 1.3k 0.7× 130 14.8k
Brian Schwartz 5.8k 0.7× 5.2k 0.7× 7.7k 1.7× 3.3k 1.0× 2.0k 1.1× 143 14.4k
Hidefumi Sasaki 7.3k 0.9× 6.4k 0.9× 5.0k 1.1× 2.7k 0.8× 714 0.4× 143 11.9k
Neal I. Lindeman 13.2k 1.6× 11.6k 1.6× 8.1k 1.8× 5.8k 1.7× 2.6k 1.4× 172 22.4k
Koji Tsuta 5.4k 0.7× 4.5k 0.6× 3.2k 0.7× 1.9k 0.5× 818 0.4× 301 9.9k
Jeffrey R. Infante 3.5k 0.4× 9.0k 1.2× 6.9k 1.5× 2.5k 0.7× 1.1k 0.6× 343 14.8k

Countries citing papers authored by Alexander Drilon

Since Specialization
Citations

This map shows the geographic impact of Alexander Drilon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander Drilon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander Drilon more than expected).

Fields of papers citing papers by Alexander Drilon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander Drilon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander Drilon. The network helps show where Alexander Drilon may publish in the future.

Co-authorship network of co-authors of Alexander Drilon

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander Drilon. A scholar is included among the top collaborators of Alexander Drilon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander Drilon. Alexander Drilon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Repetto, Matteo, Marina Chiara Garassino, Herbert H. Loong, et al.. (2024). NTRK gene fusion testing and management in lung cancer. Cancer Treatment Reviews. 127. 102733–102733. 7 indexed citations
2.
Thawani, Rajat, Matteo Repetto, Clare Keddy, et al.. (2024). TKI type switching overcomes ROS1 L2086F in ROS1 fusion-positive cancers. npj Precision Oncology. 8(1). 175–175. 5 indexed citations
3.
Murciano‐Goroff, Yonina R., Christina J. Falcon, Sabrina T. Lin, et al.. (2023). Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib. Journal of Thoracic Oncology. 18(5). 620–627. 12 indexed citations
4.
Drilon, Alexander, Vivek Subbiah, Oliver Gautschi, et al.. (2022). Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 41(2). 385–394. 119 indexed citations breakdown →
5.
Yun, Mi Ran, Dong Hwi Kim, Seok‐Young Kim, et al.. (2020). Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(13). 3287–3295. 74 indexed citations
6.
Rosen, Ezra Y., Debra A. Goldman, Jaclyn F. Hechtman, et al.. (2019). TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research. 26(7). 1624–1632. 115 indexed citations
7.
Benayed, Ryma, Michael Offin, Kerry Mullaney, et al.. (2019). High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research. 25(15). 4712–4722. 289 indexed citations breakdown →
8.
Harding, James J., Andrew X. Zhu, Todd M. Bauer, et al.. (2019). A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research. 25(17). 5202–5211. 32 indexed citations
9.
Chiang, Sarah, Paolo Cotzia, David M. Hyman, et al.. (2018). NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. The American Journal of Surgical Pathology. 42(6). 791–798. 171 indexed citations
10.
Offin, Michael, Hira Rizvi, Megan Tenet, et al.. (2018). Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers. Clinical Cancer Research. 25(3). 1063–1069. 230 indexed citations
11.
Suzawa, Ken, Michael Offin, Daniel Lu, et al.. (2018). Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer. Clinical Cancer Research. 25(4). 1248–1260. 83 indexed citations
12.
Hayashi, Takuo, Patrice Desmeules, Roger S. Smith, et al.. (2017). RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non–Small Cell Lung Carcinomas Sensitive to MEK Inhibition. Clinical Cancer Research. 24(6). 1436–1447. 50 indexed citations
13.
Somwar, Romel, James D. Joseph, Roger S. Smith, et al.. (2016). Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clinical Cancer Research. 23(12). 2981–2990. 49 indexed citations
14.
Rekhtman, Natasha, M. Catherine Pietanza, Matthew D. Hellmann, et al.. (2016). Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets. Clinical Cancer Research. 22(14). 3618–3629. 325 indexed citations breakdown →
15.
Paik, Paul K., Alexander Drilon, Pang‐Dian Fan, et al.. (2015). Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discovery. 5(8). 842–849. 423 indexed citations breakdown →
16.
Drilon, Alexander, Lu Wang, Maria E. Arcila, et al.. (2015). Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research. 21(16). 3631–3639. 202 indexed citations
17.
Drilon, Alexander, Romel Somwar, Jacob P. Wagner, et al.. (2015). A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer. Clinical Cancer Research. 22(10). 2351–2358. 128 indexed citations
18.
Eaton, Anne, Alexia Iasonos, Mrinal M. Gounder, et al.. (2015). Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities. Clinical Cancer Research. 22(3). 553–559. 11 indexed citations
19.
Arcila, Maria E., Alexander Drilon, Brooke E. Sylvester, et al.. (2014). MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical Cancer Research. 21(8). 1935–1943. 106 indexed citations
20.
Suehara, Yoshiyuki, Maria E. Arcila, Lu Wang, et al.. (2012). Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions. Clinical Cancer Research. 18(24). 6599–6608. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James G. Christensen Breakdown of academic impact, for papers by Maria E. Arcila Breakdown of academic impact, for papers by Sai‐Hong Ignatius Ou Breakdown of academic impact, for papers by Amita Patnaik Breakdown of academic impact, for papers by Frederic J. Kaye Breakdown of academic impact, for papers by Brian Schwartz Breakdown of academic impact, for papers by Hidefumi Sasaki Breakdown of academic impact, for papers by Neal I. Lindeman Breakdown of academic impact, for papers by Koji Tsuta Breakdown of academic impact, for papers by Jeffrey R. Infante
Rankless by CCL
2026